Anticholinergics antiparkinsonian

It s use with anticholinergic antiparkinsonian drugs can lead symptoms similar to atropine poisoning. 

Hydrochloride, CnH3l,CINO, Akineton, Akinophyl. Crystals, dec 275 also reported as mp 238° (Klavehn). LDm in mice 545 mg/kg Orally, 56 mg/kg i.v. therap cat Anticholinergic, antiparkinsonian,... 

In both studies it was found that, during the period of administration of the anticholinergic antiparkinsonian drug, there was worsening of the schizophrenic symptomatology. This effect was found to be more marked in the case of chlorpromazine-treated schizophrenics and it is suggested... 

Anticholinergic drugs can be effective for tremor and dystonic features in some patients but rarely show substantial benefit for bradykinesia or other disabilities. They can be used as monotherapy or in conjunction with other antiparkinsonian drugs. They differ little from each other in therapeutic potential or adverse effects. 

Anticholinergic agents antihistamines, antiparkinsonian agents, tricyclic antidepressants, pheno-thiazines... 

Trihexyphenidyl, an antiparkinsonian drug, possesses central and peripheral anticholinergic actions, as well as a direct relaxant effect on smooth muscle. It reduces muscle rigidity and general stiffness, and has a relatively minor effect on tremors. It is used in Parkinsonism in the form of monotherapy as well as in combination with levodopa. The most common synonyms are parkopan, parkinsan, and cyclodol. 

Anticholinergic drugs - atropine, hyoscine, scopolamine, antiparkinsonian drugs, antipsychotic drugs, antihistamines, antidepressants... 

The efficacy of anticholinergic drugs in parkinsonism is likely due to the ability to block muscarinic receptors in the striatum. In the absence of the inhibitory action of dopamine, the actions of the intrastriatal cholinergic interneurons are unopposed, yielding enhanced stimulation of muscarinic receptors. Blockade of these receptors reduces striatal activity. The muscarinic antagonists exert only modest antiparkinsonian actions and thus are most commonly used during the early stages of the disease or as an adjunct to levodopa therapy. 

Preclinical studies of ziprasidone indicate that it also has a low propensity to induce EPS, which was confirmed in subsequent phase II and III studies. Furthermore, the motor symptoms evoked by ziprasidone were seldom sufficiently troublesome to warrant anticholinergic medication. In one phase III trial, not more than 25% of patients receiving 160 mg/day were prescribed an anticholinergic at any time during the 6-week treatment period. These results indicate that therapeutic doses of ziprasidone not only induce a low incidence of acute EPS, but when they occur, they are often mild and do not require antiparkinsonian medication (137). 

Common pharmacodynamic interactions involve the additive anticholinergic or antidopaminergic effects of antipsychotics. Thus, concomitantly administered antiparkinsonian agents (e.g., benztropine) may increase the chances of toxicity (e.g., delirium) while dopamimetic agents (e.g., levodopa) may counteract the antipsychotic or neurotoxic effects of these agents. 

Physostigmine, given intravenously, counteracts both the peripheral and central side effects of atropine and other anticholinergic drugs such as thioridazine (neuroleptic), imipramine (antidepressant), and benztropine (antiparkinsonian medication). 

Antiparkinsonian drugs possessing anticholinergic properties (e.g., trihexyphenidyl and ethopropazine)... 

Therapeutic Function Antiparkinsonian, Anticholinergic Chemical Name l,l-Diphenyl-3-piperidino-l-propanol hydrochloride Common Name Pridinol Ridinol Structural Formula ... 

---